fund UVM technologies on the path to commercialization.fund qualified startup ventures based on UVM research.support retention of a highly technical workforce within Vermont.qualifications of project team members and their ability to complete project plan.projected ability of innovation to sustain competitive advantage.commercial potential and business viability, including protection by patent or copyright.probability of attracting future investments or licensing within Vermont.potential to contribute to local and state economic development. ![]() These awards are not for basic science development or refinement of technology. (Current and previous UVMVentures awardees are eligible to apply.) Criteria for SelectionĪwards are made on a competitive basis that takes into consideration the quality of the application, including: This competition is open to UVM faculty or staff who have filed an Invention Disclosure with UVM Innovations and have met with them, indicating an interest to pursue commercial opportunities. Applications will be reviewed as they are received and the funds may be awarded before the submission deadline of. This award will provide hard-to-get financial support for final validation of prototypes and other proof-of-principle work and to initiate the early phases of scaling up production which will enhance the prospect of success of UVM start-ups and licenses. The Office of the Vice President for Research (OVPR) is issuing this Call for Proposals for projects that are ready to accelerate the commercialization of technology developed at the University of Vermont and provide next-generation employment opportunities throughout Vermont. PathShodh’s current production capacity is about one lakh tests per month, and we can scale this up further by augmenting the manufacturing infrastructure,” Kumar said.Closed for FY22 applications. ![]() “We plan to deploy the product in the market in the next couple of weeks. PathShodh has received the license to manufacture the test for sale from the Central Drugs Standard Control Organisation (CDSCO). The technology also includes on-board memory to store more than one lakh real-time test results, touch screen display, rechargeable battery, Bluetooth connectivity to smartphone and cloud storage, capabilities to map the patient data to Aadhar number and the possibility of connecting test data through APIs to Aarogya Setu. The results are automatically displayed by the handheld reader. This platform interfaces with disposable test strips and immunoreceptors specific to Covid-19 antibodies. The test uses a Lab-on-Palm platform called “anuPathTM” which has also been developed by PathShod. The technique will also play a big role in elucidating seroconversion response to Covid-19 vaccines, and thereby play a supporting role in vaccination programmes in the future,” explained Professor Navakanta Bhat, Dean, Centre for Nano Science and Engineering (CeNSE), IISc, who is also the co-founder of PathShodh Healthcare. “The capability to quantify the Covid-19 antibody concentration will be crucial in estimating the declining antibody response over time and hence its possible impact on immunity against recurrence of infection. ![]() ![]() IISc added that PathShodh’s technique, which is protected through US and Indian patent applications, is a major departure from the qualitative rapid antibody tests in the market, which are primarily based on the lateral flow ELISA technique. It can work with venous or capillary (finger-prick) whole blood samples as well as serum samples.” Vinay Kumar, CEO and co-founder of PathShodh said that “This novel technology can detect Covid-19 antibodies all the way down to the nanomolar concentration. Hence, those antibody tests which target the S1 spike protein are more representative of an immune response against infection compared to those that target the Nucleocapsid (N) protein. The S1 protein has a Receptor Binding Domain (RBD) which latches on to the host cell’s ACE2 receptors before infection. Invented by PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID) at the Indian Institute of Science (IISc), the test can measure the electrochemical redox activity of IgM and IgG antibodies specific to the Sars-CoV-2 Spike Glycoprotein (S1). The test can determine levels of Covid-prompted IgM and IgG antibodies. Researchers at the Indian Institute of Science (IISc) have made a breakthrough development of a semi-quantitative electrochemical ELISA test for Covid-19.
0 Comments
Leave a Reply. |